Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events

Leonie Müller-Jensen; Samuel Knauss; Lorena Ginesta Roque; Christian Schinke; Smilla K. Maierhof; Frederik Bartels; Carsten Finke; Kristin Rentzsch; Claas Ulrich; Raphael Mohr; Werner Stenzel; Matthias Endres; Wolfgang Boehmerle; Petra Huehnchen

Data in Brief (Apr 2024)

Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events

Leonie Müller-Jensen,
Samuel Knauss,
Lorena Ginesta Roque,
Christian Schinke,
Smilla K. Maierhof,
Frederik Bartels,
Carsten Finke,
Kristin Rentzsch,
Claas Ulrich,
Raphael Mohr,
Werner Stenzel,
Matthias Endres,
Wolfgang Boehmerle,
Petra Huehnchen

Affiliations

Leonie Müller-Jensen: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany; Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Academy, (Junior) Clinician Scientist Program, Charitéplatz 1, 10117 Berlin, Germany
Samuel Knauss: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany; Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Academy, (Junior) Clinician Scientist Program, Charitéplatz 1, 10117 Berlin, Germany
Lorena Ginesta Roque: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany
Christian Schinke: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany; Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Academy, (Junior) Clinician Scientist Program, Charitéplatz 1, 10117 Berlin, Germany
Smilla K. Maierhof: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany; Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; Einstein Center for Neurosciences Berlin (ECN) at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
Frederik Bartels: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany; Berlin Institute of Health at Charité, Universitätsmedizin Berlin, BIH Academy, (Junior) Clinician Scientist Program, Charitéplatz 1, 10117 Berlin, Germany
Carsten Finke: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany; Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; Humboldt-Universität zu Berlin, Berlin School of Mind and Brain, Berlin, Germany
Kristin Rentzsch: Clinical Immunological Laboratory Prof. Dr. med. Winfried Stöcker, Groß Grönau, Germany
Claas Ulrich: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venerology and Allergology, Charitéplatz 1, 10117 Berlin, Germany; Collegium Medicum Berlin GmbH, Luisenstrasse 54/55, 10117 Berlin, Germany
Raphael Mohr: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Charité Campus Virchow, Augustenburger Platz 1, 13353 Berlin, Germany
Werner Stenzel: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neuropathology, Charitéplatz 1, 10117 Berlin, Germany
Matthias Endres: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany; Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, NeuroCure Cluster of Excellence, 10117 Berlin, Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Center for Stroke Research Berlin, 10117 Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases, 10117 Berlin, Berlin, Germany; DHZK (German Center for Cardiovascular Research), partner site Berlin, 10117 Berlin, Berlin, Germany
Wolfgang Boehmerle: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany; Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, NeuroCure Cluster of Excellence, 10117 Berlin, Berlin, Germany; Corresponding author at: Department of Neurology with Experimental Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1 | 10117 Berlin, Germany.
Petra Huehnchen: Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology with Experimental Neurology, Charitéplatz 1, 10117 Berlin, Berlin, Germany; Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany; Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, NeuroCure Cluster of Excellence, 10117 Berlin, Berlin, Germany

Journal volume & issue: Vol. 53
p. 110062

Abstract

Read online

The rise of cancer immunotherapy has been a milestone in clinical oncology. Above all, immune checkpoint inhibitor treatment (ICI) with monoclonal antibodies targeting programmed cell death protein 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) has improved survival rates for an increasing number of malignancies. However, despite the clinical benefits, ICI-related autoimmunity has become a significant cause of non-relapse-related morbidity and mortality. Neurological immune-related adverse events (irAE-n) are particularly severe toxicities with a high risk for chronic illness, long-term steroid dependency, and early ICI treatment termination. While the clinical characteristics of irAE-n are well described, little is known about underlying immune mechanisms and potential biomarkers. Recently, high frequencies of neuronal autoantibodies in patients with irAE-n have been reported, however, their clinical relevance is unclear.Here, we present a dataset on neuronal autoantibody profiles in ICI-treated cancer patients with and without irAE-n, which was generated to investigate the potential role of neuronal autoantibodies in ICI-induced autoimmunity. Between September 2017 and January 2022 serum samples of 29 cancer patients with irAE-n post-ICI treatment) and 44 cancer control patients without high-grade immune-related adverse events (irAEs, n = 44 pre- and post-ICI treatment) were collected and tested for a large panel of brain-reactive and neuromuscular autoantibodies using indirect immunofluorescence and immunoblot assays. Prevalence of autoantibodies was compared between the groups and correlated with clinical characteristics such as outcome and irAE-n manifestation. These data represent the first systematic comparison of neuronal autoantibody profiles between ICI-treated cancer patients with and without irAE-n, providing valuable information for both researchers and clinicians. In the future, this dataset may be valuable for meta-analyses on the prevalence of neuronal autoantibodies in cancer patients.

Published in Data in Brief

ISSN: 2352-3409 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Medicine (General): Computer applications to medicine. Medical informatics; Science: Science (General)
Website: http://www.journals.elsevier.com/data-in-brief/

About the journal

Abstract

Keywords